Dermatofibrosarcoma protuberans

Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.

Section editor
Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN, USA
Last updated on 2024-07-23:
1 regimens on this page
2 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.


All lines of therapy

Imatinib monotherapy

Regimen variant #1, 400 mg/day

Study Dates of enrollment Evidence
Rutkowski et al. 2010 (SWOG S0345) 2005-2006 Phase 2, fewer than 20 pts

Targeted therapy

48-week course


Regimen variant #2, 800 mg/day

Study Dates of enrollment Evidence
Rutkowski et al. 2010 (EORTC 62027) 2004-2007 Phase 2, fewer than 20 pts (RT)

Targeted therapy

Continued indefinitely, unless complete (R0) surgical resection became possible

References

  1. EORTC 62027: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00085475
  2. SWOG S0345: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00084630